Our molecular diagnostic tests and developments in one place.
genosmart DX is a bioinformatics and genomics platform that can be used in clinical diagnostic environments as well as for research purposes. It was designed to handle large-volume, parallel sequencing data. The system implements the processing of sequencing data, the automation of analysis workflows, and the clinical interpretation of results in a unified, scalable technological environment.
A blood plasma-based (ctDNA) liquid biopsy service developed for breast tumors, designed to track the molecular profile of the tumor over time. Molecular changes measured across serial samples can provide supplementary information for following the therapeutic response and the course of the disease, and can help with the early identification of resistance mutations, often before clinical or radiological progression.
A blood-based, multimodal liquid biopsy we are developing to detect early-stage breast cancer. Alongside circulating tumour DNA it examines platelet-bound RNA markers, so that the result reads several signal sources together. In development; market entry planned for 2027.
A urine-based, non-invasive molecular test supporting prostate cancer risk assessment, based on the detection of the TMPRSS2–ERG gene fusion frequently associated with prostate tumors. Sampling is done from a simple urine sample without prostate massage, which makes it gentle and possible to perform at home.
The next step after PC-Alarm Focus: a gentle, urine-based prostate cancer risk assessment built on the joint evaluation of several markers instead of one. Its aim is more precise decision support for the urologist, as a supplement to PSA-based work-up. In development; market entry planned for 2027.
A blood plasma-based (ctDNA) liquid biopsy test related to lung tumors, focusing on the detection and follow-up of oncogenic alterations relevant to targeted treatments. It can help with the early identification of molecular changes and the emergence of resistance mutations alongside therapy, thereby supporting the timely fine-tuning of treatment strategy.
A 55-gene, NGS-based solid tumor panel test (from FFPE tumor tissue or plasma sample) for the identification of clinically relevant mutations, copy number alterations, and gene fusions. The structured report focuses on therapeutic decision support: it highlights alterations linked to targeted treatments, resistance mutations, and predictive markers associated with PARP inhibitors and immunotherapy.
Our diagnostics move forward along four lines: from monitoring treatment towards early detection, from a single marker towards reading markers together, from sampling in the laboratory towards a sample that fits an ordinary day, and from data towards the clinical decision. Our new tests come out of these directions.
The Monitor family tracks the molecular changes of a known tumour during treatment. The Alarm family turns the same liquid biopsy foundation the other way: towards signalling a tumour's presence at an early stage, starting with breast cancer.
Alongside circulating tumour DNA we are bringing in new signal sources, such as platelet-bound RNA markers, and in urine-based tests the joint evaluation of several markers instead of a single gene fusion. The result is built from several mutually reinforcing signals rather than one.
Blood and urine, gentle, and where possible collected at home. The aim is not to bend the patient's life around the laboratory, but to fit the laboratory into life.
Every new test is built on the same platform: genosmart DX keeps the processing, analysis and clinical interpretation of sequencing data in one auditable workflow, so a new marker or a new sample type means a new module, not a new system.
Our developments run in academic and clinical collaborations.
Our research directions in detail
